Literature DB >> 32880053

Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.

Aldo Carnevale1,2, Mario Silva3, Elisa Maietti4, Gianluca Milanese3, Marta Saracco5, Simone Parisi6, Elena Bravi7, Fabio De Gennaro8, Eugenio Arrigoni7, Flavio Cesare Bodini9, Enrico Fusaro6, Carlo Alberto Scirè10, Nicola Sverzellati3, Alarico Ariani11.   

Abstract

The objective of this study was to determine the correlation between functional and radiological longitudinal change in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), and to test the OMERACT definition of clinically meaningful progression of pulmonary function tests (PFTs) for the prediction of ILD radiological evolution. We retrospectively retrieved high-resolution computed tomography (HRCT) studies and PFTs including DLco, both available at two time-points and performed within 6 months of each other, in SSc patients. A subset of patients was selected using a 12-24-month clinically oriented interval (n = 58). The extent of ILD at HRCT was scored according to a visual semi-quantitative method (SQCT). The correlation of absolute change (Δ) in the SQCT score with change in FVC and DLco was examined using Pearson's correlation coefficient. The concordance between the OMERACT criteria (≥ 10% FVC relative decline; or 5-10% FVC and ≥ 15% DLco relative decline) and SQCT categorical change (5% and 10%) was investigated. A total of 129 patients were enrolled. During 12-24-month follow-up, ΔSQCT was negatively correlated with ΔFVC (r = - 0.487, p = 0.0001) and ΔDLco (r = - 0.298, p = 0.023). Ten patients demonstrated CT progression ΔSQCT > 5%, among whom 5 with ΔSQCT > 10%. OMERACT criteria identified 25 patients with progressive SSc-ILD, of whom only 5 presented ΔSQCT > 5 and 3 presented ΔSQCT > 10%. In conclusion, change in radiological extent of SSc-ILD was correlated to functional decline in a limited time-frame. Repeated HRCT after 12-24 months may be useful for the longitudinal characterization of ILD evolution in patients with stable pulmonary function. Conversely, functional changes are suggestive of a concurrent radiological progression only after this interval. Key Points • In SSc patients, chest HRCT performed every 12-24 months can detect minimal but significant changes in ILD extent, even in subjects with stable pulmonary function. • PFT changes in 12-24 months are related to the radiological ILD progression. • OMERACT criteria might overlook patients with radiological progression. • Repeated chest HRCT may be useful for monitoring SSc-ILD when performed within 12 to 24 months from baseline in order to promptly detect progression and possibly impact on prognosis.

Entities:  

Keywords:  Follow-up studies; Interstitial lung diseases; Systemic sclerosis; Tomography (X-ray computed)

Mesh:

Year:  2020        PMID: 32880053     DOI: 10.1007/s10067-020-05375-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Authors:  Yossra A Suliman; Rucsandra Dobrota; Dörte Huscher; Thi D L Nguyen-Kim; Britta Maurer; Suzana Jordan; Rudolf Speich; Thomas Frauenfelder; Oliver Distler
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 3.  CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.

Authors:  David M Hansell; Jonathan G Goldin; Talmadge E King; David A Lynch; Luca Richeldi; Athol U Wells
Journal:  Lancet Respir Med       Date:  2015-05-11       Impact factor: 30.700

4.  Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity.

Authors:  Nicola Sverzellati; Mario Silva; Valeria Seletti; Carlotta Galeone; Stefano Palmucci; Sara Piciucchi; Carlo Vancheri; Venerino Poletti; Sara Tomassetti; Ronald Karwoski; Brian J Bartholmai
Journal:  Eur Radiol       Date:  2020-01-31       Impact factor: 5.315

5.  Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.

Authors:  A U Wells; D M Hansell; M B Rubens; A D King; D Cramer; C M Black; R M du Bois
Journal:  Arthritis Rheum       Date:  1997-07

Review 6.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 7.  Interstitial lung disease in systemic sclerosis: where do we stand?

Authors:  Susanna Cappelli; Silvia Bellando Randone; Gianna Camiciottoli; Amato De Paulis; Serena Guiducci; Marco Matucci-Cerinic
Journal:  Eur Respir Rev       Date:  2015-09

8.  Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

Authors:  Demosthenes Bouros; Athol U Wells; Andrew G Nicholson; Thomas V Colby; Vlasis Polychronopoulos; Panos Pantelidis; Patricia L Haslam; Dimitris A Vassilakis; Carol M Black; Roland M du Bois
Journal:  Am J Respir Crit Care Med       Date:  2002-06-15       Impact factor: 21.405

9.  Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.

Authors:  Marie Hudson; Deborah Assayag; Melissa Caron; Benjamin D Fox; Andrew Hirsch; Russell Steele; Rebecca Gaudreau-Taillefer; Solène Tatibouet; Lawrence Rudski; Murray Baron
Journal:  Clin Rheumatol       Date:  2013-06-04       Impact factor: 2.980

10.  Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis.

Authors:  Alarico Ariani; Mario Silva; Elena Bravi; Simone Parisi; Marta Saracco; Fabio De Gennaro; Cristian Caimmi; Francesco Girelli; Maria De Santis; Alessandro Volpe; Federica Lumetti; Vanessa Hax; Markus Bredemeier; Veronica Alfieri; Daniele Santilli; Flavio Cesare Bodini; Gianluca Lucchini; Flavio Mozzani; Valeria Seletti; Emanuele Bacchini; Eugenio Arrigoni; Dilia Giuggioli; Rafael Chakr; Luca Idolazzi; Giuseppina Bertorelli; Davide Imberti; Emanuele Michieletti; Giuseppe Paolazzi; Enrico Fusaro; Alfredo Antonio Chetta; Carlo Alberto Scirè; Nicola Sverzellati
Journal:  RMD Open       Date:  2019-02-14
View more
  1 in total

Review 1.  Management of Connective Tissue Disease-related Interstitial Lung Disease.

Authors:  Sakir Ahmed; Rohini Handa
Journal:  Curr Pulmonol Rep       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.